Product Description
OBP-301 is a conditionally-restricted, replication-competent adenovirus derived from human adenovirus type 5 (Ad-5) that adds a human Telomerase Reverse Transcriptase (hTERT) gene promoter; it replicates only in tumor cells to cause lysis. It may enhance RT and may cause immunogenic cell death. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS262)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer
Phase 1: Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04391049 |
NRG-GI007 | P1 |
Active, not recruiting |
Squamous Cell Carcinoma|Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2024-10-06 |
2024-10-12 |
Primary Completion Date|Primary Endpoints|Treatments |
|
NCT06340711 |
NCT06340711 | P2 |
Recruiting |
Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer |
2026-04-01 |
12% |
2024-05-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
jRCT1080225033 |
jRCT1080225033 | P2 |
Completed |
Esophageal Cancer |
2024-06-30 |
|||
NCT03921021 |
NCT03921021 | P2 |
Completed |
Esophageal Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2023-06-20 |
49% |
2023-07-28 |